The molecular biology of HIV latency: breaking and restoring the Tat-dependent transcriptional circuit

Purpose of reviewDespite the remarkable success of intensive antiretroviral drug therapy in blocking the HIV replication, the virus persists in a small number of cells in which HIV has been transcriptionally silenced. This review will focus on recent insights into the HIV transcriptional control mechanisms that provide the biochemical basis for understanding latency. Recent findingsLatency arises when the regulatory feedback mechanism driven by HIV Tat expression is disrupted. Small changes in transcriptional initiation, induced by epigenetic silencing, can lead to restrictions in Tat levels and entry of proviruses into latency. In resting memory T-cells, which carry the bulk of the latent viral pool, additional restrictions limiting cellular levels of the essential Tat cofactor P-TEFb and the transcription initiation factors nuclear factor kappa B and nuclear factor of activated T cells ensure that the provirus remains silenced unless the host cell is activated. SummaryStrategies to purge the latent proviral pool require nontoxic activator molecules. The multiple restrictions imposed on latent proviruses that need to be overcome suggest that proviral reactivation will not be achieved when only a single reactivation step is targeted but will require both removal of epigenetic blocks and the activation of P-TEFb. Alternatively, new inhibitors that block proviral reactivation could be developed.

[1]  C. Van Lint,et al.  HIV Persistence and the Prospect of Long-Term Drug-Free Remissions for HIV-Infected Individuals , 2010, Science.

[2]  M. Saag,et al.  Hit-and-Run Stimulation: a Novel Concept To Reactivate Latent HIV-1 Infection without Cytokine Gene Induction , 2010, Journal of Virology.

[3]  A. Burlingame,et al.  HIV-1 Tat and host AFF4 recruit two transcription elongation factors into a bifunctional complex for coordinated activation of HIV-1 transcription. , 2010, Molecular cell.

[4]  Yves Levy,et al.  HIV-1 Tat assembles a multifunctional transcription elongation complex and stably associates with the 7SK snRNP. , 2010, Molecular cell.

[5]  C. Van Lint,et al.  CpG methylation controls reactivation of HIV from latency , 2010, Retrovirology.

[6]  T. Tahirov,et al.  Crystal structure of HIV-1 Tat complexed with human P-TEFb , 2010, Nature.

[7]  J. Karn,et al.  Establishment of HIV Latency in Primary CD4+ Cells Is due to Epigenetic Transcriptional Silencing and P-TEFb Restriction , 2010, Journal of Virology.

[8]  T. Okamoto,et al.  Involvement of Histone H3 Lysine 9 (H3K9) Methyltransferase G9a in the Maintenance of HIV-1 Latency and Its Reactivation by BIX01294* , 2010, The Journal of Biological Chemistry.

[9]  Hao Zhang,et al.  Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation. , 2009, The Journal of clinical investigation.

[10]  Aidong Han,et al.  Structural basis of HIV-1 activation by NF-kappaB--a higher-order complex of p50:RelA bound to the HIV-1 LTR. , 2009, Journal of molecular biology.

[11]  Amy S. Espeseth,et al.  Expression of latent human immunodeficiency type 1 is induced by novel and selective histone deacetylase inhibitors , 2009, AIDS.

[12]  Geneviève Boucher,et al.  HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation , 2009, Nature Medicine.

[13]  M. Tremblay,et al.  TLR5 stimulation is sufficient to trigger reactivation of latent HIV-1 provirus in T lymphoid cells and activate virus gene expression in central memory CD4+ T cells. , 2009, Virology.

[14]  John O. Woods,et al.  Analysis of Human Immunodeficiency Virus Type 1 Viremia and Provirus in Resting CD4+ T Cells Reveals a Novel Source of Residual Viremia in Patients on Antiretroviral Therapy , 2009, Journal of Virology.

[15]  S J Gange,et al.  Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy , 2009, Proceedings of the National Academy of Sciences.

[16]  L. Altucci,et al.  "Shock and kill" effects of class I-selective histone deacetylase inhibitors in combination with the glutathione synthesis inhibitor buthionine sulfoximine in cell line models for HIV-1 quiescence. , 2009, Retrovirology.

[17]  Angelika Pedal,et al.  Acetylation of cyclin T1 regulates the equilibrium between active and inactive P‐TEFb in cells , 2009, The EMBO journal.

[18]  Susan Little,et al.  Latently-infected CD4+ T cells are enriched for HIV-1 Tat variants with impaired transactivation activity. , 2009, Virology.

[19]  Namshin Kim,et al.  Human Immunodeficiency Virus Integration Efficiency and Site Selection in Quiescent CD4+ T Cells , 2009, Journal of Virology.

[20]  Amy S. Espeseth,et al.  A Limited Group of Class I Histone Deacetylases Acts To Repress Human Immunodeficiency Virus Type 1 Expression , 2009, Journal of Virology.

[21]  D. Hazuda,et al.  The Challenge of Finding a Cure for HIV Infection , 2009, Science.

[22]  D. Margolis,et al.  Pharmaceutical approaches to eradication of persistent HIV infection , 2009, Expert Reviews in Molecular Medicine.

[23]  O. Kutsch,et al.  Determinants of the Establishment of Human Immunodeficiency Virus Type 1 Latency , 2009, Journal of Virology.

[24]  Priya S. Shah,et al.  Control of Stochastic Gene Expression by Host Factors at the HIV Promoter , 2009, PLoS pathogens.

[25]  A. Trkola,et al.  HIV rebounds from latently infected cells, rather than from continuing low-level replication , 2008, Proceedings of the National Academy of Sciences.

[26]  J. Karn,et al.  Epigenetic Silencing of Human Immunodeficiency Virus (HIV) Transcription by Formation of Restrictive Chromatin Structures at the Viral Long Terminal Repeat Drives the Progressive Entry of HIV into Latency , 2008, Journal of Virology.

[27]  Tina Lenasi,et al.  Transcriptional interference antagonizes proviral gene expression to promote HIV latency. , 2008, Cell host & microbe.

[28]  R. Siliciano,et al.  Orientation-dependent regulation of integrated HIV-1 expression by host gene transcriptional readthrough. , 2008, Cell host & microbe.

[29]  Qiang Zhou,et al.  PP2B and PP1alpha cooperatively disrupt 7SK snRNP to release P-TEFb for transcription in response to Ca2+ signaling. , 2008, Genes & development.

[30]  J. Karn,et al.  CBF‐1 promotes transcriptional silencing during the establishment of HIV‐1 latency , 2007, The EMBO journal.

[31]  M. L. Simpson,et al.  Transient-mediated fate determination in a transcriptional circuit of HIV , 2007, Nature Genetics.

[32]  D. Gilmour,et al.  Negative Elongation Factor NELF Represses Human Immunodeficiency Virus Transcription by Pausing the RNA Polymerase II Complex* , 2007, Journal of Biological Chemistry.

[33]  M. Marsden,et al.  Primary Cell Model for Activation-Inducible Human Immunodeficiency Virus , 2007, Journal of Virology.

[34]  W. Greene,et al.  Sustained Induction of NF-κB Is Required for Efficient Expression of Latent Human Immunodeficiency Virus Type 1 , 2007, Journal of Virology.

[35]  F. Dequiedt,et al.  Recruitment of chromatin‐modifying enzymes by CTIP2 promotes HIV‐1 transcriptional silencing , 2007, The EMBO journal.

[36]  A. Knezevich,et al.  Suv39H1 and HP1γ are responsible for chromatin‐mediated HIV‐1 transcriptional silencing and post‐integration latency , 2007, The EMBO journal.

[37]  Eric Verdin,et al.  The SWI/SNF Chromatin-remodeling Complex Is a Cofactor for Tat Transactivation of the HIV Promoter* , 2006, Journal of Biological Chemistry.

[38]  Paul Shinn,et al.  Retroviral DNA Integration: Viral and Cellular Determinants of Target-Site Selection , 2006, PLoS pathogens.

[39]  E. Verdin,et al.  NF‐κB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation , 2006, The EMBO journal.

[40]  D. Nickle,et al.  HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir. , 2005, The Journal of clinical investigation.

[41]  Jared E. Toettcher,et al.  Stochastic Gene Expression in a Lentiviral Positive-Feedback Loop: HIV-1 Tat Fluctuations Drive Phenotypic Diversity , 2005, Cell.

[42]  Mary K. Lewinski,et al.  Genome-Wide Analysis of Chromosomal Features Repressing Human Immunodeficiency Virus Transcription , 2005, Journal of Virology.

[43]  Van Trung Nguyen,et al.  Binding of the 7SK snRNA turns the HEXIM1 protein into a P‐TEFb (CDK9/cyclin T) inhibitor , 2004, The EMBO journal.

[44]  R. Siliciano,et al.  Resting CD4+ T Cells from Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Individuals Carry Integrated HIV-1 Genomes within Actively Transcribed Host Genes , 2004, Journal of Virology.

[45]  Mario Roederer,et al.  T-Cell Subsets That Harbor Human Immunodeficiency Virus (HIV) In Vivo: Implications for HIV Pathogenesis , 2004, Journal of Virology.

[46]  B. Peterlin,et al.  Dynamics of Human Immunodeficiency Virus Transcription: P-TEFb Phosphorylates RD and Dissociates Negative Effectors from the Transactivation Response Element , 2004, Molecular and Cellular Biology.

[47]  M. Giacca,et al.  Regulation of HIV‐1 gene expression by histone acetylation and factor recruitment at the LTR promoter , 2003, The EMBO journal.

[48]  J. Zack,et al.  Identification of T cell-signaling pathways that stimulate latent HIV in primary cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[49]  A. Link,et al.  Inhibition of P-TEFb (CDK9/Cyclin T) kinase and RNA polymerase II transcription by the coordinated actions of HEXIM1 and 7SK snRNA. , 2003, Molecular cell.

[50]  J. Stroud,et al.  Structure of NFAT1 bound as a dimer to the HIV-1 LTR κB element , 2003, Nature Structural Biology.

[51]  R. Siliciano,et al.  Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells , 2003, Nature Medicine.

[52]  E. Verdin,et al.  HIV reproducibly establishes a latent infection after acute infection of T cells in vitro , 2003, The EMBO journal.

[53]  R. Siliciano,et al.  Resting CD4+ T Lymphocytes but Not Thymocytes Provide a Latent Viral Reservoir in a Simian Immunodeficiency Virus-Macaca nemestrina Model of Human Immunodeficiency Virus Type 1-Infected Patients on Highly Active Antiretroviral Therapy , 2003, Journal of Virology.

[54]  J. Karn,et al.  Phosphorylation of the RNA Polymerase II Carboxyl-Terminal Domain by CDK9 Is Directly Responsible for Human Immunodeficiency Virus Type 1 Tat-Activated Transcriptional Elongation , 2002, Molecular and Cellular Biology.

[55]  M. Tremblay,et al.  Nuclear Factor of Activated T Cells Is a Driving Force for Preferential Productive HIV-1 Infection of CD45RO-expressing CD4+ T Cells* , 2002, The Journal of Biological Chemistry.

[56]  J. Karn,et al.  Spt5 Cooperates with Human Immunodeficiency Virus Type 1 Tat by Preventing Premature RNA Release at Terminator Sequences , 2002, Molecular and Cellular Biology.

[57]  Tamás Kiss,et al.  7SK small nuclear RNA binds to and inhibits the activity of CDK9/cyclin T complexes , 2001, Nature.

[58]  Qiang Zhou,et al.  The 7SK small nuclear RNA inhibits the CDK9/cyclin T1 kinase to control transcription , 2001, Nature.

[59]  Eric Verdin,et al.  Duration of Nuclear NF-κB Action Regulated by Reversible Acetylation , 2001, Science.

[60]  T. Rana,et al.  DSIF and NELF Interact with RNA Polymerase II Elongation Complex and HIV-1 Tat Stimulates P-TEFb-mediated Phosphorylation of RNA Polymerase II and DSIF during Transcription Elongation* , 2001, The Journal of Biological Chemistry.

[61]  Christina M. R. Kitchen,et al.  Generation of HIV latency during thymopoiesis , 2001, Nature Medicine.

[62]  R. Gaynor,et al.  Domains in the SPT5 Protein That Modulate Its Transcriptional Regulatory Properties , 2000, Molecular and Cellular Biology.

[63]  R. Lempicki,et al.  HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[64]  Anthony S. Fauci,et al.  AIDS: Re-emergence of HIV after stopping therapy , 1999, Nature.

[65]  G. Nolan,et al.  Host Control of HIV-1 Parasitism in T Cells by the Nuclear Factor of Activated T Cells , 1998, Cell.

[66]  M. Giacca,et al.  HIV-1 tat transactivator recruits p300 and CREB-binding protein histone acetyltransferases to the viral promoter. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[67]  G. Nabel,et al.  Interaction of Human Immunodeficiency Virus Type 1 Tat with the Transcriptional Coactivators p300 and CREB Binding Protein , 1998, Journal of Virology.

[68]  K. Jeang,et al.  Activation of Integrated Provirus Requires Histone Acetyltransferase , 1998, The Journal of Biological Chemistry.

[69]  T. Chun,et al.  Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[70]  A. Rao,et al.  Nuclear Factor of Activated T Cells (NFAT)-dependent Transactivation Regulated by the Coactivators p300/CREB-binding Protein (CBP) , 1998, The Journal of experimental medicine.

[71]  Ping Wei,et al.  A Novel CDK9-Associated C-Type Cyclin Interacts Directly with HIV-1 Tat and Mediates Its High-Affinity, Loop-Specific Binding to TAR RNA , 1998, Cell.

[72]  R Brookmeyer,et al.  Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. , 1997, Science.

[73]  D. Baltimore,et al.  The kappaB sites in the human immunodeficiency virus type 1 long terminal repeat enhance virus replication yet are not absolutely required for viral growth , 1997, Journal of virology.

[74]  G. Nolan,et al.  The T cell activation factor NF-ATc positively regulates HIV-1 replication and gene expression in T cells. , 1997, Immunity.

[75]  J. Karn,et al.  The human immunodeficiency virus long terminal repeat includes a specialised initiator element which is required for Tat-responsive transcription. , 1995, Journal of molecular biology.

[76]  M. Groudine,et al.  Cellular latency in human immunodeficiency virus-infected individuals with high CD4 levels can be detected by the presence of promoter-proximal transcripts. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[77]  G. Nabel,et al.  A cooperative interaction between NF‐kappa B and Sp1 is required for HIV‐1 enhancer activation. , 1993, The EMBO journal.

[78]  C. Van Lint,et al.  Chromatin disruption in the promoter of human immunodeficiency virus type 1 during transcriptional activation. , 1993, The EMBO journal.

[79]  H. Olsen,et al.  Contribution of the TATA motif to Tat-mediated transcriptional activation of human immunodeficiency virus gene expression , 1992, Journal of virology.

[80]  M. Martin,et al.  Contribution of NF-kappa B and Sp1 binding motifs to the replicative capacity of human immunodeficiency virus type 1: distinct patterns of viral growth are determined by T-cell types , 1991, Journal of virology.

[81]  G. Nabel,et al.  An inducible transcription factor activates expression of human immunodeficiency virus in T cells , 1987, Nature.

[82]  R. Tjian,et al.  Activation of the AIDS retrovirus promoter by the cellular transcription factor, Sp1. , 1986, Science.

[83]  Alberto Bosque,et al.  Induction of HIV-1 latency and reactivation in primary memory CD4+ T cells. , 2009, Blood.

[84]  M. Tremblay,et al.  TLR 5 stimulation is suf fi cient to trigger reactivation of latent HIV-1 provirus in T lymphoid cells and activate virus gene expression in central memory CD 4 + T cells , 2009 .

[85]  Larry W. Moreland,et al.  Nuclear factor of activated T-cells , 2004 .

[86]  M. Tyers,et al.  Duration of Nuclear NF-kB Action Regulated by Reversible Acetylation , 2001 .

[87]  Alan S. Perelson,et al.  The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy , 2000, Nature Medicine.